Lexeo Therapeutics Inc. has signed a definitive agreement to acquire Mantle Therapeutics Inc. and has entered into new research collaborations in a move to expand its position in Friedreich’s ataxia ...

The Federal Aviation Administration last week granted Boeing’s 777 freighter a few more years of production, waiving looming emissions requirements for up to 35 new aircraft. Without that exemption, ...

[EDITOR'S NOTE: This story has been updated with a statement from GE Aerospace.] Boeing says FAA approval to begin extended range twin operations (ETOPS) flight tests on the 777-9, the final ...

Investment firm 777 Partners has agreed to take a bankruptcy loan from Leadenhall Capital Partners, turning away from its longtime financial backer Advantage Capital Holdings and aligning with a ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor event on ...

The retrofit marks a major change for American’s largest widebody aircraft and brings the 777-300ER in line with the premium cabin design introduced on the airline’s Boeing 787-9 and Airbus A321XLR ...

American Airlines’ biggest plane has finally received a major makeover as the carrier continues to double down on premium offerings. American’s first Boeing 777-300ER to be retrofitted with more ...

American Airlines is adding more premium seats to its Boeing 777-300ER planes used on long-haul routes as US carriers increasingly chase higher-spending travelers. The airline is also phasing out ...

Forbes contributors publish independent expert analyses and insights. Charlotte-based reporter Ted Reed covers airlines and airline labor. This voice experience is generated by AI. Learn more. This ...

Investment firm 777 Partners won interim court approval Thursday for a portion of a proposed bankruptcy loan after lenders clashed over who should finance the defunct investment firm and control the ...

Verastem Oncology (Nasdaq: VSTM) announced that the first patient has been dosed in the TARGET-D 203 Phase 2 registration-directed trial ... This is a premium only article. To continue reading this ...

i The price is displayed as a monthly rate (VAT excl.), but payment is made annually. Please refer to our subscription terms for more details.